Protherics PLC Notification of Directors' Interests London, UK; Brentwood, TN, US; 18 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 15 June 2007, in accordance with Sections 3.1.4R(1)(a) and 3.1.4R(1)(b) of the FSA Disclosure and Transparency Rules, the Company received notification that, on 15 June 2007, Garry Watts, Non-executive Director of Protherics, acquired 50,000 ordinary 2p shares in the Company at a price of 58.5 pence per share. Following the above notification, Garry Watts holds a beneficial interest in 50,000 ordinary shares in Protherics (0.01% of the issued share capital of the Company). The issued share capital of the Company is 339,234,721 Ordinary Shares of 2p each. | Ends | For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113 New York: John Capodanno, Jonathan Birt +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange
Protherics PLC announces Directors Interests
| Source: Protherics PLC
Cheshire, UK--(Marketwire - June 18, 2007) -